Purpose: To investigate the topical effect of dorzolamide versus ketorolac on retinitis pigmentosa (RP) and Usher's syndrome (US) macular edema. Methods: Prospective, randomized and interventional study. A total of 28 eyes of 18 patients were included. Five eyes had US, 23 had RP. Fifteen eyes were allocated to ketorolac tromethamine 0.5% (4 drops daily regimen) and 13 eyes to dorzolamide hydrochloride 2% (3 drops daily regimen) treatment groups. Snellen's best-corrected visual acuity (BCVA), foveal thickness (FT) and foveal zone thickness (FZT) measured by Stratus® optical coherence tomography (OCT) were evaluated at baseline, 1, 3, 6 and 12 months after treatment. Results: Patients assigned to ketorolac had a baseline BCVA of 0.37 ± 0.17 logMAR which improved at the end of 1 year to 0.28 ± 0.16 (p = 0.02). Three eyes (20%) of 2 patients improved by 7 letters or more. Mean FT and FZT did not change significantly during the study follow-up. After 1 year of treatment, 4 eyes (27%) of 3 patients showed an improvement of at least 16% of FT and 11% of FZT. Patients assigned to dorzolamide had a baseline BCVA of 0.48 ± 0.34 logMAR which improved in the first 6 months (0.40 ± 0.30; p = 0.01), with a decrease at 1 year (0.42 ± 0.27; p = 0.20). Seven eyes (54%) of 5 patients had an improvement of 7 letters or more. Mean FT and FZT did not change significantly either. After 1 year of treatment, 3 eyes (23%) of 2 patients showed an improvement of at least 16% on FT and 11% on FZT. Conclusions: Results suggest that dorzolamide and ketorolac might improve visual acuity and therefore be of interest in selected cases. No relationship between retinal thickness fluctuation and visual acuity was found. Sample size was a limitation to the study.

Keywords:
Dorzolamide, Ketorolac, Cystoid macular edema, Retinitis pigmentosa, Usherߣs syndrome
1.
Marmor MF, Aguirre G, Arden GB, et al: Retinitis pigmentosa: a symposium on terminology and methods of examination. Ophthalmology 1983;90:126-131.
2.
Pruett RC: Retinitis pigmentosa: clinical observations and correlations. Trans Am Ophthalmol Soc 1983;81:693-735.
3.
Berson EL: Retinitis pigmentosa. The Friedenwald lecture. Invest Ophthalmol Vis Sci 1993;34:1659-1676.
4.
Grover S, Fishman GA, Anderson RJ, et al: Rate of visual field loss in retinitis pigmentosa. Ophthalmology 1997;104:460-465.
5.
Fishman GA, Kumar A, Joseph ME, et al: Usher's syndrome. Ophthalmic and neuro-otologic findings suggesting genetic heterogeneity. Arch Ophthalmol 1983;101:1367-1374.
6.
Hope CI, Bundey S, Proops D, et al: Usher syndrome in the city of Birmingham - prevalence and clinical classification. Br J Ophthalmol 1997;81:46-53.
7.
Rosenberg T, Haim M, Hauch AM, et al: The prevalence of Usher syndrome and other retinal dystrophy-hearing impairment associations. Clin Genet 1997;51:314-321.
8.
Smith RJ, Berlin CI, Hejtmancik JF, et al: Clinical diagnosis of the Usher syndromes. Usher Syndrome Consortium. Am J Med Genet 1994;50:32-38.
9.
Tsilou ET, Rubin BI, Caruso RC, et al: Usher syndrome clinical types I and II: could ocular symptoms and signs differentiate between the two types? Acta Ophthalmol Scand 2002;80:196-201.
10.
Ikeda Y, Hisatomi T, Yoshida N, et al: The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 2012;250:809-814.
11.
Fishman GA, Maggiano JM, Fishman M: Foveal lesions seen in retinitis pigmentosa. Arch Ophthalmol 1997;95:1993-1996.
12.
Hirakawa H, Iijima H, Gohdo T, et al: Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. Am J Ophthalmol 1999;128:185-191.
13.
Hajali M, Fishman GA, Anderson RJ: The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol 2008;92:1065-1068.
14.
Fishman GA, Anderson RJ, Lam BL, et al: Prevalence of foveal lesions in type 1 and type 2 Usher's syndrome. Arch Ophthalmol 1995;113:770-773.
15.
Walia S, Fishman GA, Hajali M: Prevalence of cystic macular lesions in patients with Usher II syndrome. Eye 2009;23:1206-1209.
16.
Sandberg MA, Brockhurst RJ, Gaudio AR, et al: The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci 2005;46:3349-3354.
17.
Sandberg MA, Brockhurst RJ, Gaudio AR, et al: Visual acuity is related to parafoveal retinal thickness in patients with retinitis pigmentosa and macular cysts. Invest Ophthalmol Vis Sci 2008;49:4568-7452.
18.
Apushkin MA, Fishman GA, Janowicz MJ: Monitoring cystoid macular edema by optical coherence tomography in patients with retinitis pigmentosa. Ophthalmology 2004;111:1899-1904.
19.
Stanga PE, Downes SM, Ahuja RM, et al: Comparison of optical coherence tomography and fluorescein angiography in assessing macular edema in retinal dystrophies: preliminary results. Int Ophthalmol 2001;23:321-325.
20.
Hirakawa H, Iijima H, Gohdo T, et al: Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. Am J Ophthalmol 1999;128:185-191.
21.
Saraiva VS, Sallum JM, Farah ME: Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 2003;34:398-400.
22.
Ozdemir H, Karacorlu M, Karacorlu S: Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand 2005;83:248-251.
23.
Kim JE: Intravitreal triamcinolone for treatment of cystoid macular edema associated with retinitis pigmentosa. Retina 2006;26:1094-1096.
24.
Wang C, Hu J, Bernstein PS, Teske MP, et al: Intravitreal injection of triamcinolone acetonide for macular edema due to retinitis pigmentosa and other retinal diseases. Adv Exp Med Biol 2006;572:309-314.
25.
Scorolli L, Morara M, Meduri A, et al: Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone. Arch Opththalmol 2007;125:759-764.
26.
Melo GB, Farah ME, Aggio FB: Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa. Acta Ophthalmol Scand 2007;85:461-463.
27.
Newsome DA, Blacharski PA: Grid photocoagulation for macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 1987;103:161-166.
28.
Heckenlively JR: Grid photocoagulation for macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 1987;104:94-95.
29.
Garcia-Arumi J, Martinez V, Sararols L, et al: Vitreoretinal surgery of cystoid macular edema associated with retinitis pigmentosa. Ophthalmology 2003;110:1164-1169.
30.
Wolfensberger TJ: The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol 1999;97:387-397.
31.
Grover S, Apushkin MA, Fishman GA: Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Opththalmol 2006;141:850-858.
32.
Fishman GA, Apushkin MA: Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol 2007;91:743-745.
33.
Genead MA, Fishman GA: Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and Usher syndrome. Arch Ophthalmol 2010;128:1146-1150.
34.
Mitchell JA, Warner TD: COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 2006;5:75-86.
35.
Nichols J, Snyder R: Topical nonsteroidal anti-inflammatory agents in ophthalmology. Curr Opin Ophthalmol 1998;9:40-44.
36.
Pallapies D, Salinger A, Meyer zum Gottesberge A, et al: Effects of lysine onixinate and ketorolac tromethamine on prostanoid release from various rat organs incubated ex vivo. Life Sci 1995;57:83-89.
37.
Sivaprasad S, Bunce C, Patel N: Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database Syst Rev 2005;1:CD004239.
38.
Flach AJ: The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 1998;96:557-634.
39.
Flach AJ, Dolan BJ, Irvine AR: Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol 1987;103:479-486.
40.
Flach AJ, Jampol LM, Weinberg D, et al: Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991;112:514-519.
41.
Heier JS, Awh CC, Busbee BG, et al: Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina 2009;29:1310-1313.
42.
Warren KA, Bahrani H, Fox JE: NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 2010;30:260-266.
43.
Grover S, Fishman GA, Gilbert LD, et al: Reproducibility of visual acuity measurements in patients with retinitis pigmentosa. Retina 1985;17:33-37.
44.
Grover S, Apushkin MA, Fishman GA: Topical dorzolamide in the management of chronic cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 2006;141:850-858.
45.
Cox SN, Hay E, Bird AC: Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol 1988;106:1190-1195.
46.
Moldow B, Sander B, Larsen M, et al: The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular edema. Graefes Arch Clin Exp Ophthalmol 1988;236:881-889.
47.
Oishi A, Otani A, Sasahara M, et al: Photoreceptor integrity and visual acuity in cystoid macular oedema associated with retinitis pigmentosa. Eye 2009;23:1411-1416.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.